Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P.
2008. Global trends in emerging infectious diseases. Nature 451:990–993.
Taylor LH, Latham SM, woolhouse MEJ. 2001. Risk factors for human disease
emergence. Philos Trans R Soc Lond B Biol Sci 356:983–989.
Rupasinghe R, Chomel BB, Martínez-López B. 2022. Climate change and
zoonoses: A review of the current status, knowledge gaps, and future trends. Acta
Trop 226:106225.
Kobayashi Y, Kato H, Yamagishi T, Shimada T, Matsui T, Yoshikawa T, Kurosu T,
Shimojima M, Morikawa S, Hasegawa H, Saijo M, Oishi K. 2020. Severe fever
with thrombocytopenia syndrome, Japan, 2013–2017. Emerg Infect Dis 26:692–
699.
Robles NJC, Han HJ, Park S-J, Choi YK. 2018. Epidemiology of severe fever and
thrombocytopenia syndrome virus infection and the need for therapeutics for the
prevention. Clin Exp Vaccine Res 7:43.
Muehlenbachs A, Fata CR, Lambert AJ, Paddock CD, Velez JO, Blau DM, Staples
JE, Karlekar MB, Bhatnagar J, Nasci RS, Zaki SR. 2014. Heartland virusassociated death in Tennessee. Clin Infect Dis 59:845–850.
Schoch CL, Ciufo S, Domrachev M, Hotton CL, Kannan S, Khovanskaya R, Leipe
D, Mcveigh R, O’Neill K, Robbertse B, Sharma S, Soussov V, Sullivan JP, Sun L,
Turner S, Karsch-Mizrachi I. 2020. NCBI Taxonomy: a comprehensive update on
curation, resources and tools. Database (Oxford) 2020.
McMullan LK, Folk SM, Kelly AJ, MacNeil A, Goldsmith CS, Metcalfe MG,
Batten BC, Albariño CG, Zaki SR, Rollin PE, Nicholson WL, Nichol ST. 2012. A
new phlebovirus associated with severe febrile illness in Missouri. N Engl J Med
367:834–841.
Kato H, Yamagishi T, Shimada T, Matsui T, Shimojima M, Saijo M, Oishi K. 2016.
Epidemiological and clinical features of severe fever with thrombocytopenia
syndrome in Japan, 2013–2014. PLoS One 11:e0165207.
Fill M-MA, Compton ML, McDonald EC, Moncayo AC, Dunn JR, Schaffner W,
Bhatnagar J, Zaki SR, Jones TF, Shieh W-J. 2016. Novel clinical and pathologic
findings in a Heartland virus–associated death. Clin Infect Dis 64:510-512.
Yu X-J, Liang M-F, Zhang S-Y, Liu Y, Li J-D, Sun Y-L, Zhang L, Zhang Q-F,
Popov VL, Li C, Qu J, Li Q, Zhang Y-P, Hai R, Wu W, Wang Q, Zhan F-X, Wang
X-J, Kan B, Wang S-W, Wan K-L, Jing H-Q, Lu J-X, Yin W-W, Zhou H, Guan XH, Liu J-F, Bi Z-Q, Liu G-H, Ren J, Wang H, Zhao Z, Song J-D, He J-R, Wan T,
61
20.
Zhang J-S, Fu X-P, Sun L-N, Dong X-P, Feng Z-J, Yang W-Z, Hong T, Zhang Y,
Walker DH, Wang Y, Li D-X. 2011. Fever with thrombocytopenia associated with
a novel Bunyavirus in China. N Engl J Med 364:1523–1532.
Santiago FW, Covaleda LM, Sanchez-Aparicio MT, Silvas JA, Diaz-Vizarreta AC,
Patel JR, Popov V, Yu X, García-Sastre A, Aguilar P v. 2014. Hijacking of RIG-I
signaling proteins into virus-induced cytoplasmic structures correlates with the
inhibition of type I interferon responses. J Virol 88:4572–4585.
Lee SH, Kim HJ, Byun JW, Lee MJ, Kim NH, Kim DH, Kang HE, Nam HM. 2017.
Molecular detection and phylogenetic analysis of severe fever with
thrombocytopenia syndrome virus in shelter dogs and cats in the Republic of Korea.
Ticks Tick Borne Dis 8:626–630.
Niu G, Li J, Liang M, Jiang X, Jiang M, Yin H, Wang Z, Li C, Zhang Q, Jin C,
Wang X, Ding S, Xing Z, Wang S, Bi Z, Li D. 2013. Severe fever with
thrombocytopenia syndrome virus among domesticated animals, China. Emerg
Infect Dis 19:756–763.
Xing B, Li X-K, Zhang S-F, Lu Q-B, Du J, Zhang P-H, Yang Z-D, Cui N, Guo CT, Cao W-C, Zhang X-A, Liu W. 2018. Polymorphisms and haplotypes in the
promoter of the TNF-α gene are associated with disease severity of severe fever
with thrombocytopenia syndrome in Chinese Han population. PLoS Negl Trop Dis
12:e0006547.
Nyakarahuka L, Kankya C, Krontveit R, Mayer B, Mwiine FN, Lutwama J,
Skjerve E. 2016. How severe and prevalent are Ebola and Marburg viruses? A
systematic review and meta-analysis of the case fatality rates and seroprevalence.
BMC Infect Dis 16:708.
Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 2010. Human fatal Zaire
Ebola virus infection is associated with an aberrant innate immunity and with
massive lymphocyte apoptosis. PLoS Negl Trop Dis 4:e837.
Mühlberger E, Weik M, Volchkov VE, Klenk H-D, Becker S. 1999. Comparison
of the transcription and replication strategies of Marburg virus and Ebola virus by
using artificial replication systems. J Virol 73:2333–2342.
Banerjee A, Pal A, Pal D, Mitra P. 2017. Ebolavirus interferon antagonists-protein
interaction perspectives to combat pathogenesis. Brief Funct Genomics 17:392–
401.
Basler CF, Amarasinghe GK. 2009. Evasion of interferon responses by Ebola and
21.
Marburg viruses. J Interferon Cytokine Res 9:511-20.
Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF.
12.
13.
14.
15.
16.
17.
18.
19.
62
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
2010. Basic residues within the Ebolavirus VP35 protein are required for its viral
polymerase cofactor function. J Virol 84:10581–10591.
Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe
GK. 2009. Structure of the Ebola VP35 interferon inhibitory domain. PNAS
106:411-6.
Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q, Ding S, Guan X, Huo X, Li C,
Qu J, Wang Q, Zhang S, Zhang Y, Wang S, Xu A, Bi Z, Li D. 2012. Host cytokine
storm is associated with disease severity of severe fever with thrombocytopenia
syndrome. J Infect Dis 206:1085–1094.
Hu C, Guo C, Yang Z, Wang L, Hu J, Qin S, Cui N, Peng W, Liu K, Liu W, Cao W.
2015. The severe fever with thrombocytopenia syndrome bunyavirus (SFTSV)
antibody in a highly endemic region from 2011 to 2013: A comparative serological
study. Am J Trop Med Hyg 92:479–481.
Kimura T, Fukuma A, Shimojima M, Yamashita Y, Mizota F, Yamashita M, Otsuka
Y, Kan M, Fukushi S, Tani H, Taniguchi S, Ogata M, Kurosu T, Morikawa S, Saijo
M, Shinomiya H. 2018. Seroprevalence of severe fever with thrombocytopenia
syndrome (SFTS) virus antibodies in humans and animals in Ehime prefecture,
Japan, an endemic region of SFTS. J Infect Chemother 24:802–806.
Ning Y-J, Wang M, Deng M, Shen S, Liu W, Cao W-C, Deng F, Wang Y-Y, Hu Z,
Wang H. 2014. Viral suppression of innate immunity via spatial isolation of
TBK1/IKKε from mitochondrial antiviral platform. J Mol Cell Biol 6:324–337.
Wu X, Qi X, Qu B, Zhang Z, Liang M, Li C, Cardona CJ, Li D, Xing Z. 2014.
Evasion of antiviral immunity through sequestering of TBK1/IKKε/IRF3 into viral
inclusion bodies. J Virol 88:3067–3076.
Li J, Li J, Miyahira A, Sun J, Liu Y, Cheng G, Liang H. 2012. Crystal structure of
the ubiquitin-like domain of human TBK1. Protein Cell 3:383–391.
Ikeda F, Hecker CM, Rozenknop A, Nordmeier RD, Rogov V, Hofmann K, Akira
S, Dötsch V, Dikic I. 2007. Involvement of the ubiquitin-like domain of
TBK1/IKK-i kinases in regulation of IFN-inducible genes. EMBO Journal
26:3451–3462.
Qu B, Qi X, Wu X, Liang M, Li C, Cardona CJ, Xu W, Tang F, Li Z, Wu B, Powell
K, Wegner M, Li D, Xing Z. 2012. Suppression of the interferon and NF-κB
responses by severe fever with thrombocytopenia syndrome virus. J Virol
86:8388–8401.
Moriyama M, Igarashi M, Koshiba T, Irie T, Takada A, Ichinohe T. 2018. Two
conserved amino acids within the NSs of SFTS phlebovirus are essential for anti63
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
interferon activity. J Virol JVI.00706-18.
Ning YJ, Feng K, Min YQ, Deng F, Hu Z, Wang H. 2017. Heartland virus NSs
protein disrupts host defenses by blocking the TBK1 kinase–IRF3 transcription
factor interaction and signaling required for interferon induction. J Biol Chem
292:16722–16733.
Zhang C, Shang G, Gui X, Zhang X, Bai X, Chen ZJ. 2019. Structural basis of
STING binding with and phosphorylation by TBK1. Nature 567:394–398.
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K.
2001. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 29:308–
311.
Team RC. 2018. R: A Language and Environment for Statistical Computin.
https://www.r-project.org/.
Pothlichet J, Burtey A, Kubarenko A V., Caignard G, Solhonne B, Tangy F, BenAli M, Quintana-Murci L, Heinzmann A, Chiche JD, Vidalain PO, Weber ANR,
Chignard M, Si-Tahar M. 2009. Study of human RIG-I polymorphisms identifies
two variants with an opposite impact on the antiviral immune response. PLoS One
4.
Sun Q, Jin C, Zhu L, Liang M, Li C, Cardona CJ, Li D, Xing Z. 2015. Host
responses and regulation by NFκB signaling in the liver and liver epithelial cells
infected with a novel tick-borne Bunyavirus. Sci Rep 5:11816.
Wang Y, Yin Y, Lan X, Ye F, Tian K, Zhao X, Yin H, Li D, Xu H, Liu Y, Zhu Q.
2017. Molecular characterization, expression of chicken TBK1 gene and its effect
on IRF3 signaling pathway. PLoS One 12:e0177608.
Outlioua A, Pourcelot M, Arnoult D. 2018. The role of optineurin in antiviral type
I interferon production. Front Immunol 9.
Sasai M, Shingai M, Funami K, Yoneyama M, Fujita T, Matsumoto M, Seya T.
2006. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic
pathways in type I IFN induction. The Journal of Immunology 177:8676–8683.
Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, Vega MA de La, Soka MJ,
Wahl V, Griffiths A, Bollinger L, Kuhn JH. 2020. Ebola virus disease Nat Rev Dis
Primers 6:13 .
Amarasinghe GK, Aréchiga Ceballos NG, Banyard AC, Basler CF, Bavari S,
Bennett AJ, Blasdell KR, Briese T, Bukreyev A, Caì Y, Calisher CH, Campos
Lawson C, Chandran K, Chapman CA, Chiu CY, Choi KS, Collins PL, Dietzgen
RG, Dolja V V., Dolnik O, Domier LL, Dürrwald R, Dye JM, Easton AJ, Ebihara
H, Echevarría JE, Fooks AR, Formenty PBH, Fouchier RAM, Freuling CM,
64
43.
44.
45.
46.
47.
48.
49.
50.
Ghedin E, Goldberg TL, Hewson R, Horie M, Hyndman TH, Jiāng D, Kityo R,
Kobinger GP, Kondō H, Koonin E V., Krupovic M, Kurath G, Lamb RA, Lee B,
Leroy EM, Maes P, Maisner A, Marston DA, Mor SK, Müller T, Mühlberger E,
Ramírez VMN, Netesov S V., Ng TFF, Nowotny N, Palacios G, Patterson JL,
Pawęska JT, Payne SL, Prieto K, Rima BK, Rota P, Rubbenstroth D, Schwemmle
M, Siddell S, Smither SJ, Song Q, Song T, Stenglein MD, Stone DM, Takada A,
Tesh RB, Thomazelli LM, Tomonaga K, Tordo N, Towner JS, Vasilakis N,
Vázquez-Morón S, Verdugo C, Volchkov VE, Wahl V, Walker PJ, Wang D, Wang
LF, Wellehan JFX, Wiley MR, Whitfield AE, Wolf YI, Yè G, Zhāng YZ, Kuhn JH.
2018. Taxonomy of the order Mononegavirales: update 2018. Arch Virol
163:2283–2294.
Cross RW, Mire CE, Feldmann H, Geisbert TW. 2018. Post-exposure treatments
for Ebola and Marburg virus infections. Nat Rev Drug Discov 17:413–434.
Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, Juste
J, Quetglas J, Savji N, de la Cruz Martínez M, Herrera JE, Pizarro M, Hutchison
SK, Echevarría JE, Lipkin WI, Tenorio A. 2011. Discovery of an ebolavirus-like
filovirus in europe. PLoS Pathog 7:1–8.
Yang X Lou, Tan CW, Anderson DE, Jiang R Di, Li B, Zhang W, Zhu Y, Lim XF,
Zhou P, Liu XL, Guan W, Zhang L, Li SY, Zhang YZ, Wang LF, Shi ZL. 2019.
Characterization of a filovirus (Měnglà virus) from Rousettus bats in China. Nat
Microbiol 4:390–395.
Messaoudi I, Amarasinghe GK, Basler CF. 2015. Filovirus pathogenesis and
immune evasion: Insights from Ebola virus and Marburg virus. Nat Rev Microbiol
13:663–676.
Prins KC, Cardenas WB, Basler CF. 2009. Ebola virus protein VP35 impairs the
function of interferon regulatory factor-activating kinases IKK and TBK-1. J Virol
83:3069–3077.
Reid SP, Cárdenas WB, Basler CF. 2005. Homo-oligomerization facilitates the
interferon-antagonist activity of the ebolavirus VP35 protein. Virology 341:179–
189.
Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M,
Klenk H-D, Palese P, García-Sastre A. 2003. The Ebola virus VP35 protein inhibits
activation of interferon regulatory factor 3. J Virol 77:7945–56.
Cardenas WB, Loo Y-M, Gale M, Hartman AL, Kimberlin CR, Martinez-Sobrido
L, Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds double-stranded
RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J
65
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
Virol 80:5168–5178.
Hartman AL, Towner JS, Nichol ST. 2004. A C-terminal basic amino acid motif of
Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays
high identity with the RNA-binding domain of another interferon antagonist, the
NS1 protein of influenza A virus. Virology 328:177–184.
Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix
JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK.
2010. Structural basis for dsRNA recognition and interferon antagonism by Ebola
VP35. Nat Struct Mol Biol 17:165–172.
Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid StP, Ramanan
P, Cardenas WB, Amarasinghe GK, Volchkov VE, Basler CF. 2010. Mutations
abrogating VP35 interaction with double-stranded RNA render Ebola virus
avirulent in Guinea Pigs. J Virol 84:3004–3015.
Hartman AL, Bird BH, Towner JS, Antoniadou Z-A, Zaki SR, Nichol ST. 2008.
Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of
Ebola virus. J Virol 82:2699–2704.
Jones S, Thornton JM. 1997. Analysis of protein-protein interaction sites using
surface patches. J Mol Biol 272:121–132.
Jones S, Thornton JM. 1997. Prediction of protein-protein interaction sites using
patch analysis. J Mol Biol 272:133–143.
Niwa H, Yamamura K, Miyazaki J. 1991. Efficient secletion for high-expression
transformants with a novel eukaryotic vector. Gene 108:193–199.
Kondoh T, Manzoor R, Nao N, Maruyama J, Furuyama W, Miyamoto H, Shigeno
A, Kuroda M, Matsuno K, Fujikura D, Kajihara M, Yoshida R, Igarashi M, Takada
A. 2017. Putative endogenous filovirus VP35-like protein potentially functions as
an IFN antagonist but not a polymerase cofactor. PLoS One 12:1–17.
Watanabe S, Noda T, Halfmann P, Jasenosky L, Kawaoka Y. 2007. Ebola virus
(EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect
Dis 196:S284–S290.
Watanabe S, Watanabe T, Noda T, Feldmann H, Jasenosky LD, Takada A, Kawaoka
Y. 2004. Production of novel Ebola virus-like particles from cDNAs : an alternative
to Ebola virus generation by reverse genetics. J Virol 78:999–1005.
Changula K, Yoshida R, Noyori O, Marzi A, Miyamoto H, Ishijima M, Yokoyama
A, Kajihara M, Feldmann H, Mweene AS, Takada A. 2013. Mapping of conserved
and species-specific antibody epitopes on the Ebola virus nucleoprotein. Virus Res
176:83–90.
66
62.
63.
64.
65.
66.
67.
68.
69.
70.
Kimberlin CR, Bornholdt ZA, Li S, Woods VL, MacRae IJ, Saphire EO. 2010.
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune
suppression. Proc Natl Acad Sci U S A 107:314–319.
Haasnoot J, De Vries W, Geutjes EJ, Prins M, De Haan P, Berkhout B. 2007. The
ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3:0794–
0803.
Becker S, Rinne C, Hofsäß U, Klenk HD, Mühlberger E. 1998. Interactions of
Marburg virus nucleocapsid proteins. Virology 249:406–417.
Marnolia A, Toepak EP, Tambunan USF. 2018. Fragment-based lead compound
design to inhibit Ebola VP35 through computational studies. Int J of GEOMATE
15:65–71.
Zhang YJ, Ding JN, Zhong H, Sun CP, Han JG. 2017. Molecular dynamics
exploration of the binding mechanism and properties of single-walled carbon
nanotube to WT and mutant VP35 FBP region of Ebola virus. J Biol Phys 43:149–
165.
Brown CS, Lee MS, Leung DW, Wang T, Xu W, Luthra P, Anantpadma M,
Shabman RS, Melito LM, MacMillan KS, Borek DM, Otwinowski Z, Ramanan P,
Stubbs AJ, Peterson DS, Binning JM, Tonelli M, Olson MA, Davey RA, Ready
JM, Basler CF, Amarasinghe GK. 2014. In silico derived small molecules bind the
filovirus VP35 protein and inhibit its polymerase co-factor activity. J Mol Biol
426:2045–2058.
Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek
DM, Otwinowski Z, Liu G, Huh J, Basler CF, Amarasinghe GK. 2012. Structural
basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl
Acad Sci U S A 109:20661–20666.
Feagins AR, Basler CF. 2015. Lloviu virus VP24 and VP35 proteins function as
innate immune antagonists in human and bat cells. Virology 485:145–152.
Williams CG, Gibbons JS, Keiffer TR, Luthra P, Edwards MR, Basler CF. 2020.
Impact of Měnglà virus proteins on human and bat innate immune pathways. J
Virol 94.
67
...
論文の公開元へ
